SCPH merger: insiders cashed at $5.35 plus CVRs up to $1.00
Rhea-AI Filing Summary
scPharmaceuticals Inc. reporting person Rachael Nokes (CFO and Treasurer) reported transactions tied to a merger with MannKind Corporation. On 10/07/2025 a tender offer and subsequent merger completed under a Merger Agreement that provided $5.35 per share in cash plus one non-tradable contingent value right (CVR) per share, with CVRs eligible for up to $1.00 aggregate upon certain milestones.
As a result, 30,386 directly held common shares were disposed and 125,675 other common shares (including RSUs) were surrendered for cash and CVRs, leaving 0 shares held following the transactions. Outstanding options with exercise prices below $5.35 were cancelled and cashed out for the excess value, and corresponding RSU awards were converted into cash and CVRs per the agreement.
Positive
- Cash consideration of $5.35 per share provided immediate liquidity for surrendered common shares and RSUs
- CVRs issued for each share preserve contingent upside up to $1.00 per CVR tied to specific milestones
- In-the-money options were cashed out, removing potential future dilution from those awards
Negative
- Reporting person’s common stock ownership reduced to 0 shares after the transactions, eliminating direct equity stake
- Outstanding options and RSUs were cancelled, removing any remaining exercise-based upside except via CVRs
- CVR payments are contingent on regulatory and net sales milestones and are not guaranteed
Insights
Insider holdings were fully cashed out under merger terms on the closing date.
The reporting person executed dispositions on 10/07/2025 where common stock, RSUs and in-the-money options were converted into cash at $5.35 per share plus one CVR per share under the Merger Agreement. This converted equity compensation into immediate cash value and contingent upside via CVRs.
The main dependency is achievement of the CVR milestones that can add up to $1.00 per CVR; timeline and payout depend on the specified regulatory and net sales triggers. Investors can monitor milestone disclosures and any CVR payment announcements governing aggregate payouts.
Equity incentive instruments were accelerated, vested, and cancelled for cash consideration.
Per the agreement, each outstanding RSU was vested and exchanged for cash and a CVR, and options with exercise prices below $5.35 were cashed out for the spread. The treatment eliminates future equity dilution from these specific awards but also ends potential upside for the reporting person except via CVRs.
Key items to watch are any disclosures about the number of CVRs outstanding and detailed milestone timelines; these determine residual contingent exposure and potential future cash flows.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Disposition | Stock Option (Right to Buy) | 132,670 | $0.00 | -- |
| Disposition | Stock Option (Right to Buy) | 54,700 | $0.00 | -- |
| Disposition | Stock Option (Right to Buy) | 6,426 | $0.00 | -- |
| Disposition | Stock Option (Right to Buy) | 13,850 | $0.00 | -- |
| U | Common Stock | 30,386 | $0.00 | -- |
| Disposition | Common Stock | 125,675 | $0.00 | -- |
Footnotes (1)
- In connection with the terms of an Agreement and Plan of Merger, dated as of August 24, 2025 (the "Merger Agreement"), by and among the Issuer, MannKind Corporation ("Parent") and Seacoast Merger Sub, Inc., a direct wholly owned subsidiary of Parent ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's common stock ("Common Stock") on October 7, 2025. Tendering stockholders received per share consideration of $5.35 in cash, without interest, subject to any applicable withholding taxes, plus one non-tradable contingent value right ("CVR"), representing the right to receive certain contingent payments of up to an aggregate amount of $1.00 per CVR in cash, (Continued from footnote 1) without interest, subject to any applicable withholding taxes, upon the achievement of certain regulatory and net sales milestones on or prior to the applicable milestone outside dates. After completion of the tender offer, Purchaser merged with and into the Issuer (the "Merger", and the effective time of the Merger, the "Effective Time"), with the Issuer continuing as the surviving corporation in the Merger and a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each restricted stock unit award with respect to shares of Common Stock ("RSU Award") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, became fully vested and was cancelled and converted into the right to receive (i) an amount in cash, without interest and subject to any applicable withholding taxes, equal to (A) the number of shares underlying such RSU Award immediately prior to such cancellation multiplied by (B) $5.35 and (ii) one CVR in respect of each share subject to such RSU Award. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time and that had an exercise price per share that was less than $5.35, whether or not then vested or exercisable, was cancelled and converted into the right to receive (i) an amount in cash, without interest and subject to any applicable withholding taxes, equal to (A) the total number of shares subject to such Company Option immediately prior to such cancellation multiplied by (B) the excess, if any, of (x) $5.35 over (y) the exercise price payable per share underlying such Company Option and (ii) one CVR in respect of each share subject to such Company Option.
